Literature DB >> 18997495

Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

A Giustina1, A Barkan, P Chanson, A Grossman, A Hoffman, E Ghigo, F Casanueva, A Colao, S Lamberts, M Sheppard, S Melmed.   

Abstract

The V Consensus Group Meeting on 'Guidelines for Treatment of GH Excess and GH Deficiency in the Adult' was an international workshop held on February 20-22, 2006 in Santa Monica, California, USA. The principal aim of this meeting was to provide guidelines for the evaluation and treatment of adults with either form of abnormal GH secretion: GH excess or GH deficiency. The workshop included debates as to the choice of primary treatment, discussions of the targets for adequate treatment, and concluded with presentations on open issues germane to adult GH treatment including the role of GH in malignancies, the impact of longterm treatment on bone, and a cost-benefit analysis. The meeting was comprised of 66 delegates representing 13 different countries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997495     DOI: 10.1007/bf03349263

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  169 in total

1.  Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.

Authors:  P De; D A Rees; N Davies; R John; J Neal; R G Mills; J Vafidis; J S Davies; M F Scanlon
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

Review 2.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

4.  The pathology of median neuropathy in acromegaly.

Authors:  P J Jenkins; S A Sohaib; S Akker; R R Phillips; K Spillane; J A Wass; J P Monson; A B Grossman; G M Besser; R H Reznek
Journal:  Ann Intern Med       Date:  2000-08-01       Impact factor: 25.391

5.  Growth hormone receptor antagonist improves insulin resistance in acromegaly.

Authors:  D Roderick Rose; David R Clemmons
Journal:  Growth Horm IGF Res       Date:  2002-12       Impact factor: 2.372

6.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors:  I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

7.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

8.  Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Authors:  Raquel S Jallad; Nina R C Musolino; Luiz R Salgado; Marcello D Bronstein
Journal:  Clin Endocrinol (Oxf)       Date:  2005-08       Impact factor: 3.478

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

10.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

View more
  31 in total

Review 1.  The rational use of pituitary stimulation tests.

Authors:  Stephan Petersenn; Hans-Jürgen Quabbe; Christof Schöfl; Günter K Stalla; Klaus von Werder; Michael Buchfelder
Journal:  Dtsch Arztebl Int       Date:  2010-06-25       Impact factor: 5.594

2.  How to improve effectiveness of pegvisomant treatment in acromegalic patients.

Authors:  M Ragonese; S Grottoli; P Maffei; A Alibrandi; M R Ambrosio; G Arnaldi; A Bianchi; S Puglisi; M C Zatelli; L De Marinis; E Ghigo; A Giustina; F Maffezzoni; C Martini; L Trementino; S Cannavo
Journal:  J Endocrinol Invest       Date:  2017-10-28       Impact factor: 4.256

Review 3.  Primary empty sella: Why and when to investigate hypothalamic-pituitary function.

Authors:  A Giustina; G Aimaretti; M Bondanelli; F Buzi; S Cannavò; S Cirillo; A Colao; L De Marinis; D Ferone; M Gasperi; S Grottoli; T Porcelli; E Ghigo; E degli Uberti
Journal:  J Endocrinol Invest       Date:  2010-03-05       Impact factor: 4.256

4.  Optimal use of pegvisomant in acromegaly: are we getting there?

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2014-10-28       Impact factor: 3.633

Review 5.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

6.  Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.

Authors:  Sabrina Chiloiro; Gherardo Mazziotti; Antonella Giampietro; Antonio Bianchi; Stefano Frara; Marilda Mormando; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 7.  Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials.

Authors:  Connie B Newman; John D Carmichael; David L Kleinberg
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 8.  Muscle-bone and fat-bone interactions in regulating bone mass: do PTH and PTHrP play any role?

Authors:  Nabanita S Datta
Journal:  Endocrine       Date:  2014-05-07       Impact factor: 3.633

9.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

10.  Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.

Authors:  Roberto Salvatori; Lisa B Nachtigall; David M Cook; Vivien Bonert; Mark E Molitch; Sandra Blethen; Stephen Chang
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.